Orlistat in prediabetes

Orlistat in Prediabetes

NICE suggest that a clinician should use clinical judgement on whether to offer orlistat to people with a BMI of 28.0 kg/m2 or more, as part of an overall plan for managing obesity ( take into account the person's risk and the level of weight loss and lifestyle change required to reduce this risk)

Duration:

• review the use of orlistat after 12 weeks
  • if the person has not lost at least 5% of their original body weight, use clinical judgement to decide whether to stop the orlistat
  • note however, as with adults who have type 2 diabetes, those at high risk of the condition may lose weight more slowly than average, so less strict goals may be appropriate
    
    
• only use orlistat for more than 12 months (usually for weight maintenance) after discussing the potential benefits, limitations and side effects with the person concerned

Reference:

• NICE (July 2012). Type 2 diabetes: prevention in people at high risk (Updated September 2017)
• Prediabetes (Borderline diabetes). Diabetes UK (Accessed 27/9/2017)